Stock Scorecard

Stock Summary for Black Diamond Therapeutics Inc (BDTX) - $5.89 as of 4/26/2024 7:19:12 PM EST

Total Score

12 out of 29

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for BDTX

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for BDTX

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for BDTX

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2

Bonus Criteria for BDTX

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Latest News for for BDTX

CARGO Therapeutics Names Kapil Dhingra, M.B.B.S., to Board of Directors - Cargo Therapeutics ( NASDAQ:CRGX ) 4/15/2024 8:05:00 PM
Black Diamond Therapeutics Presents Novel Real-World Evidence of the Evolving EGFR Mutation Landscape in NSCLC and the Opportunity for BDTX-1535 in an Oral Presentation at the 2024 American Association of Cancer Research Annual Meeting 4/7/2024 10:00:00 PM
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update 3/12/2024 12:00:00 PM
Black Diamond Therapeutics Announces Corporate Update and Expected 2024 Milestones - Black Diamond Therapeutic ( NASDAQ:BDTX ) 1/4/2024 1:00:00 PM
Black Diamond Therapeutics Announces Topline Results from Phase 1 Dose Escalation Trial of BDTX-1535 in Patients with Recurrent GBM 12/13/2023 12:00:00 PM
Black Diamond Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update 11/6/2023 12:45:00 PM
Black Diamond Therapeutics And 2 Other Stocks Under $3 Insiders Are Buying - Bespoke Extracts ( OTC:BSPK ) , Black Diamond Therapeutic ( NASDAQ:BDTX ) 10/20/2023 12:55:00 PM
Black Diamond Therapeutics Presents Dose Escalation Data Demonstrating Durable Responses in Patients with NSCLC from Phase 1 Trial of BDTX-1535 10/14/2023 4:30:00 PM
Black Diamond Therapeutics to Present Preclinical and Clinical Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - Black Diamond Therapeutic ( NASDAQ:BDTX ) 10/4/2023 4:14:00 PM
Black Diamond Therapeutics to Present Preclinical and Clinical Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 10/4/2023 4:14:00 PM

Financial Details for BDTX

Company Overview
Ticker BDTX
Company Name Black Diamond Therapeutics Inc
Country USA
Description Black Diamond Therapeutics, Inc., a biotechnology company, discovers and develops small molecule tumor agnostic therapies. The company is headquartered in Cambridge, Massachusetts.
Sector Name LIFE SCIENCES
Industry Name BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Most Recent Quarter 12/31/2023
Next Earnings Date 6/6/2024

Stock Price History
Last Day Price 5.89
Last Day Price Updated 4/26/2024 7:19:12 PM EST
Last Day Volume 565,162
Average Daily Volume 534,415
52-Week High 6.85
52-Week Low 1.43
Last Price to 52 Week Low 311.89%

Valuation Measures
Trailing PE N/A
Industry PE 64.46
Sector PE 56.64
5-Year Average PE -3.88
Free Cash Flow Ratio 2.32
Industry Free Cash Flow Ratio 20.47
Sector Free Cash Flow Ratio 30.65
Current Ratio Most Recent Quarter 6.82
Total Cash Per Share 2.54
Book Value Per Share Most Recent Quarter 2.26
Price to Book Ratio 2.32
Industry Price to Book Ratio 7.85
Sector Price to Book Ratio 22.15
Price to Sales Ratio Twelve Trailing Months 0.00
Industry Price to Sales Ratio Twelve Trailing Months 9.94
Sector Price to Sales Ratio Twelve Trailing Months 5.17

Share Statistics
Total Shares Outstanding 51,718,000
Market Capitalization 304,619,020
Institutional Ownership N/A

Dividends
Ex-Dividend Date N/A
Last Dividend Amount 0.00
Current Dividend Amount 0.00
Dividend Aristocrat? False
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement
Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth 9.57%
Reported EPS 12 Trailing Months -1.88
Reported EPS Past Year 0.00
Reported EPS Prior Year -1.88
Net Income Twelve Trailing Months -82,442,000
Net Income Past Year -82,442,000
Net Income Prior Year -91,169,000
Quarterly Revenue Growth YOY 0.00%
5-Year Revenue Growth 0.00%

Balance Sheet
Total Cash Most Recent Quarter 131,400,000
Total Cash Past Year 131,400,000
Total Cash Prior Year 122,807,000
Net Cash Position Most Recent Quarter 131,400,000
Net Cash Position Past Year 131,400,000
Long Term Debt Past Year 0
Long Term Debt Prior Year 0
Total Debt Most Recent Quarter 0
Equity to Debt Ratio Past Year 1.00
Equity to Debt Ratio Most Recent Quarter 1.00
Total Stockholder Equity Past Year 116,736,000
Total Stockholder Equity Prior Year 115,695,000
Total Stockholder Equity Most Recent Quarter 116,736,000

Options
Put/Call Ratio 0.00
Has Options False
Liquidity Rating

Technical Analysis
Yahoo Finance Chart Yahoo Finance Chart
MACD 0.09
MACD Signal 0.14
20-Day Bollinger Lower Band 2.00
20-Day Bollinger Middle Band 4.22
20-Day Bollinger Upper Band 6.43
Beta 2.64
RSI 51.81
50-Day SMA 3.33
200-Day SMA 10.32

System
Modified 4/26/2024 7:19:14 PM EST